標(biāo)題: Titlebook: Immunotherapy Against Lung Cancer; Emerging Opportuniti Shvetank Bhatt,Rajaraman Eri Eri,Kamal Dua Book 2024 The Editor(s) (if applicable) [打印本頁] 作者: 駝峰 時(shí)間: 2025-3-21 18:59
書目名稱Immunotherapy Against Lung Cancer影響因子(影響力)
書目名稱Immunotherapy Against Lung Cancer影響因子(影響力)學(xué)科排名
書目名稱Immunotherapy Against Lung Cancer網(wǎng)絡(luò)公開度
書目名稱Immunotherapy Against Lung Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Immunotherapy Against Lung Cancer被引頻次
書目名稱Immunotherapy Against Lung Cancer被引頻次學(xué)科排名
書目名稱Immunotherapy Against Lung Cancer年度引用
書目名稱Immunotherapy Against Lung Cancer年度引用學(xué)科排名
書目名稱Immunotherapy Against Lung Cancer讀者反饋
書目名稱Immunotherapy Against Lung Cancer讀者反饋學(xué)科排名
作者: ENACT 時(shí)間: 2025-3-21 21:25
Subiksha Maheshkumar,Diwahar Prakash,Ashwin Subramanian,Gayathri Devi Muthukumarasamy,Rishmitha Duracontrol processes to regulate synthesis of these proteins at either the transcriptional or post-transciptional level could represent an important mechanism for controlling specialized functions in normal as well as physiologically or pathologically altered cells. In order to assess transcriptional a作者: tenuous 時(shí)間: 2025-3-22 03:03 作者: conscience 時(shí)間: 2025-3-22 04:44 作者: 漸強(qiáng) 時(shí)間: 2025-3-22 11:58
Shvetank Bhatt,Shreya Sharma,Shubham Patil,Rohini Pujarits with angina pectoris obtain some relief from glyceryl trinitrate and beta-adrenergic blocking drugs, and arterial reconstructive surgery also gives symptomatic improvement to selected subjects who have angina or transient symptoms of leg or brain ischaemia. There is, however, little evidence that作者: Alienated 時(shí)間: 2025-3-22 16:49
Jayaraman Rajangam,Vasanth Raj Palanimuthu,Dinesh Kumar Upadhyay,Lucy Mohapatra,Navanita Sivaramakumhanced. The present studies were therefore carried out to determine if blood viscosity (a major flow determinant) was increased in diabetic patients, whether blood viscosity differed in patients with and without different complications, and if viscosity was influenced by metabolic control.作者: 黃瓜 時(shí)間: 2025-3-22 18:32 作者: creatine-kinase 時(shí)間: 2025-3-22 23:47 作者: Foreknowledge 時(shí)間: 2025-3-23 04:54
Nitin Verma,Komal Thapa,Neha Kanojia,Parul Sood,Jatin Kumar,Nikita Thakur,Kamal Duain this series. This comprehensive but clinical approach has necessitated the inclusion of certain subjects such as the mechanisms of tachycardia, metabolic aspects of cardiac arrhythmias and reperfusion arrhythmias, which are not directly or exclusively clinical. However, the rapid advances in thes作者: 拍下盜公款 時(shí)間: 2025-3-23 08:13 作者: 分開 時(shí)間: 2025-3-23 10:49
Arghya Kusum Dhar,Narahari N. Palei,Dilipkumar Reddy Kandulaso be useful to voice and singing teachers, and to their pupils. G. E. Arnold, Jackson, Miss. F. Winckel, Berlin B. D. Wyke, London Preface Neurologists, neuropsychologists, speech pathologists and other clinicians who care for dysphasic patients have often complained that available books on dysphas作者: 使害羞 時(shí)間: 2025-3-23 16:33
Abhishek Krishna,Elroy Saldanha,Vijay Marakala,Paul Simon,Thomas George,Raymond Anthony,Pankaj Prabhintrahemispheric specialization in brain function as well, and within the left hemisphere, much of this specialization in function constitutes the anatomy of language. Even many ostensible critics of the localizationist theories resorted to a system of language Classification that carried implicit f作者: 裝入膠囊 時(shí)間: 2025-3-23 20:40
Kangkan Sharma,Khyati Saini,Pranali Chimaniya,Sibashankar Sahu,Debasis Gantayat,Rajeev Sharma,Shvetactively examined the evolution of dysphasia in 69 non-traumatic patients and found that patients seen after 2 months had only a limited possibility of spontaneous recovery compared to patients seen before 2 months. Culton (1969) studied the recovery patterns of 21 dysphasics and concluded that the g作者: exigent 時(shí)間: 2025-3-24 02:05
Introduction to Lung Cancer,ce. When combined with cisplatin, adjuvant treatment may offer a little survival-time benefit. Radiation treatment alone may not be as effective in improving survival as chemotherapy coupled with it. Advanced NSCLC patients should get treatment in combination. Over the finest supportive care, a numb作者: Hallmark 時(shí)間: 2025-3-24 05:07
Evolution of Lung Cancer Treatment from Classical Chemotherapy to Advanced Immunotherapy, human immune system. This led to the discovery of immunotherapy and usage of monoclonal antibodies to block immune checkpoints, thereby enhancing the migration of T cells towards cancer cells. This chapter elaborates various chemotherapeutic drugs used in different stages of lung cancer, the mechan作者: Consequence 時(shí)間: 2025-3-24 09:03
Revolutionizing Lung Cancer Treatment: Recent Breakthroughs in Immunotherapy,th-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), resulting in improved treatment outcomes for lung cancer. This review will provide an overview of the current state of immuno-oncology, focusing on factors influencing the effectiveness of immunotherapies. Despite the notable succ作者: Concerto 時(shí)間: 2025-3-24 13:32 作者: 違抗 時(shí)間: 2025-3-24 18:02 作者: Myofibrils 時(shí)間: 2025-3-24 19:19 作者: Toxoid-Vaccines 時(shí)間: 2025-3-25 01:30
,IDO and TGF-β Inhibitors for the Treatment of Lung Cancer,f several diseases and disorders. It includes immune dysfunction, fibrosis, cerebrovascular diseases, and cancer. Inhibiting the TGF-β signaling pathway leads to beneficial effects in cancer. This section focuses on different targets of TGF-β signaling pathways, the most widely studied TGF-β recepto作者: 異端邪說2 時(shí)間: 2025-3-25 06:21
OX40 and CD40 Agonists for the Treatment of Lung Cancer, have shown therapeutic potential of monoclonal antibodies to resist this inhibition and/or improve tumor-antigen-specific T-cell reactions. T-cell function is specifically enhanced by the targeting of co-stimulatory members of the (TNFR) family with agonist Abs, which has produced encouraging thera作者: 畫布 時(shí)間: 2025-3-25 10:02
Exploring the Therapeutic Potential of ICOS and GITR Agonists in Lung Cancer,ion of T-cells. The ICOS/ICOSL (inducible T-cell co-stimulator ligand) pathway serves a dual function of pro-tumour as well as the antitumour function, whereas GITR is localised on various immune cells and is associated with the modulation of immune responses. Like ICOS, GITR too exhibits both activ作者: Irrigate 時(shí)間: 2025-3-25 13:12
Vaccines and Oncolytic Virus for the Treatment of Lung Cancer,sm. Lung cancer treatment holds great promise for the future thanks to the development of therapeutic cancer vaccines and oncolytic viral therapy. By using immune system to stimulate long-term memory toward tumor cells, therapeutic cancer vaccines hope to cause tumor regression with few or no advers作者: hysterectomy 時(shí)間: 2025-3-25 19:29 作者: 喊叫 時(shí)間: 2025-3-25 22:49 作者: 事情 時(shí)間: 2025-3-26 01:23 作者: 逃避系列單詞 時(shí)間: 2025-3-26 05:19
Synergistic Potential of Antigen-Specific Vaccines and Immunomodulatory Agents for Lung Cancer Treaons. In this chapter, we summarized the different types of lung cancer vaccines and its effect on host immune response. This chapter also briefly speaks about the existing pros and cons of these vaccines and their clinical efficacy. Apart from conventional treatment options such as chemotherapy, rad作者: Innocence 時(shí)間: 2025-3-26 09:17 作者: 流浪 時(shí)間: 2025-3-26 15:12
Book 2024 information to a range of audiences including clinical researchers working in the field of lung cancer, and undergraduate and postgraduate students from various disciplines such as pharmacy, microbiology, immunology, pharmacology, biotechnology, and health sciences..作者: pulmonary-edema 時(shí)間: 2025-3-26 18:11 作者: 反復(fù)拉緊 時(shí)間: 2025-3-27 01:02
Suresh Krishna Venkataramanan,Nithya Shree Raman,Karthika Rangasamy,Sree Gayathri Ganapathy,PavithraNeurologists, neuropsychologists, speech pathologists and other clinicians who care for dysphasic patients have often complained that available books on dysphas978-3-7091-8607-7978-3-7091-8605-3Series ISSN 0173-170X 作者: 緩解 時(shí)間: 2025-3-27 01:29 作者: Mutter 時(shí)間: 2025-3-27 05:40 作者: kindred 時(shí)間: 2025-3-27 13:07 作者: Counteract 時(shí)間: 2025-3-27 17:40
Book 2024iled mechanisms of checkpoint inhibitors, co-stimulatory molecules, drugs working in the immunosuppressive environment, and various vaccines for lung cancer. A chapter of the book explores the recent applications of the oncolytic virus in lung cancer treatment and discusses the potential and directi作者: 佛刊 時(shí)間: 2025-3-27 21:03
LAG-3 Inhibitors for the Treatment of Lung Cancer,ing pathways involved in its clinical trial results have shown that LAG-3 blocking Monoclonal Antibody, Relatlimab, Nivolumab, and Ipilimumab are both effective and safe. Investigation of the functional characteristics of LAG-3 may allow the development of better, non-invasive therapies for lung cancer.作者: nurture 時(shí)間: 2025-3-27 22:06
Important Biomarkers for Better Evaluation of Checkpoint Inhibitors and Other Immunotherapies in Luive value of tumour mutations, circulatory variables, immune-related parameters, and gut flora are all covered in this article along with immunotherapy treatment. Further, fresh developing biomarkers that must be confirmed in future clinical research are addressed, as well as potential indicators for illness that progresses excessively.作者: Infiltrate 時(shí)間: 2025-3-28 04:39
Immunobiology of Lung Cancer,o better understand lung carcinogenesis and provide new therapeutic strategies for the management of patients with more specific and selective lung cancer, research focusing on the function of immune cells is needed.作者: MUTED 時(shí)間: 2025-3-28 06:19
Future Perspectives of Cancer Immunotherapy for the Treatment of Lung Cancer,ssed. As immunotherapy continues to evolve, various advances such as deep learning, combinatorial immunotherapy and neoadjuvant have come to light. This chapter offers a holistic overview of these strategies, their current limitations in clinical practice and future perspectives.作者: conjunctivitis 時(shí)間: 2025-3-28 11:15
Rohini Pujari,Sujit Kumar Sah,Shvetank Bhatte of anemia and associated topics;.new emphasis on anemias oIron is essential for most forms of life, including humans. On the other hand, iron is also potentially toxic. Therefore, the control of iron metabolism and maintenance of iron hemostasis is an crucial part of many aspects of human health a作者: EPT 時(shí)間: 2025-3-28 16:49 作者: 托人看管 時(shí)間: 2025-3-28 18:58 作者: Additive 時(shí)間: 2025-3-28 23:58 作者: Leaven 時(shí)間: 2025-3-29 06:38
Yuvraj Patil,Bariz Dakhni,Shweta Kolhatkarhich supply the heart, brain and lower limbs. It is our purpose to review the possible contribution of blood rheology to these events. Recent interest in this topic probably arises for three reasons. In the last decade a number of studies have been reported which associate blood rheology factors wit作者: 擦試不掉 時(shí)間: 2025-3-29 11:09 作者: 手榴彈 時(shí)間: 2025-3-29 14:54 作者: Credence 時(shí)間: 2025-3-29 17:03
Kaustubhi Sankpal,Saurabh Morparia,Vasanti Suvarna,Manikanta Murahariumented many of the techniques, and the basic scientific and clinical observations, which have helped to open up understanding of this highly important aspect of human physiology and pathology in recent years. The text is logically divided into five sections beginning with blood cell deformability, 作者: Femine 時(shí)間: 2025-3-29 19:43 作者: OATH 時(shí)間: 2025-3-30 01:51
Nitin Verma,Komal Thapa,Neha Kanojia,Parul Sood,Jatin Kumar,Nikita Thakur,Kamal Dua textbooks on cardiac arrhythmias, some of which concentrate on one particular aspect such as drug management, electrocardiographic appearances, electrophysiological evaluation etc; and others of which are the collated reports of symposia, often dealing with detailed con- siderations of highly speci作者: 不愿 時(shí)間: 2025-3-30 06:29
Shiveena Bhatia,Shravani P. Vaidya,Apurva Sagade,Priyamvada Nair,Nikita,Rajeev Taliyan his name is usually attached.. Holter monitoring consists of an audiotape to record the ECGs and a rapid scanning device for subsequent analysis. All systems place reliance on a diary, of events which is kept by the patient so that symptoms may be correlated with ECG findings on the tape. The patie作者: debouch 時(shí)間: 2025-3-30 09:16 作者: Shuttle 時(shí)間: 2025-3-30 14:11 作者: 祖?zhèn)髫?cái)產(chǎn) 時(shí)間: 2025-3-30 17:28 作者: jungle 時(shí)間: 2025-3-30 22:56 作者: negotiable 時(shí)間: 2025-3-31 03:20 作者: Aggrandize 時(shí)間: 2025-3-31 06:25
Introduction to Lung Cancer,s a key risk factor for the disease. Small-cell carcinomas and non-small-cell carcinomas are the two types of lung cancer that may be generically categorised. Up to 75% of lung cancer cases are non-small-cell lung cancer?(NSCLC), which is more prevalent. Chest radiography, sputum cytology, bronchosc作者: 要求比…更好 時(shí)間: 2025-3-31 12:49
Immunobiology of Lung Cancer,rapy are likely to blame. A number of important immune cells, including as CD4+?and CD8+ T-lymphocytes, macrophages, dendritic cells, and natural killer cells, are involved in the pathogenesis of lung cancer. Growing knowledge about these cells points to a highly intricate and interconnected network作者: 圍巾 時(shí)間: 2025-3-31 15:36
Evolution of Lung Cancer Treatment from Classical Chemotherapy to Advanced Immunotherapy,n-small-cell lung cancer (NSCLC) is 28% and small-cell lung cancer (SCLC) is 7%. The standard care of treatment for such a deadly disease includes surgery, radiation therapy, and chemotherapy. Among these, chemotherapy is a painless treatment procedure that uses chemically formulated drugs and bioti作者: FADE 時(shí)間: 2025-3-31 18:01 作者: 積習(xí)難改 時(shí)間: 2025-3-31 22:23 作者: FLEET 時(shí)間: 2025-4-1 04:32
CTLA-4 Inhibitors for the Treatment of Lung Cancer,g cancer (NSCLC) patients are diagnosed at an advanced stage of the illness, lowering the 5-year survival rate to around 5%. Immune checkpoint inhibitors (ICIs) can restore and sustain anti-tumour immunity by inhibiting the cancer immune response’s inhibitory pathway. Programmed cell death 1 (PD-1),作者: 賠償 時(shí)間: 2025-4-1 09:57
Adoptive T-Cell Therapy for the Treatment of Lung Cancer,ortant mutational variations in the cells have resulted in the creation of molecularly targeted medicines, the efficacy of which has been hampered by the establishment of resistance mechanisms. The current technological revolution in cancer treatment has resulted in substantial medical therapy and c作者: SLUMP 時(shí)間: 2025-4-1 11:40
LAG-3 Inhibitors for the Treatment of Lung Cancer,mor response is by modulation of signaling pathways between T lymphocytes and antigen-presenting cells and reestablishment of cytotoxic T lymphocyte activity. In recent years, LAG-3 has been taken into consideration as a prognostic tumor marker for therapy of cancer because it has turned into a pote作者: Chromatic 時(shí)間: 2025-4-1 14:56
,IDO and TGF-β Inhibitors for the Treatment of Lung Cancer,the kynurenine pathway. The increased IDO activity is well correlated with many diseases and disorders. Hence, inhibition of IDO will suppress the proliferation of cancer cells and exhibit beneficial effects on cancer patients. This book chapter focuses on the structure of IDO’s active site, the pha
